Evolving HER2-Low Paradigm: Key Questions at ESMO
Transcript
HER2-low breast cancer has emerged as a clinically actionable subgroup, prompting fundamental questions about patient selection, sequencing, and long-term outcomes. This congress addresses several pivotal uncertainties — from biomarker thresholds to combination strategies — that will shape how we integrate new agents into practice.